GILEAD SCIENCES 885823 (Seite 113)
eröffnet am 20.02.06 13:18:36 von
neuester Beitrag 13.02.24 21:17:08 von
neuester Beitrag 13.02.24 21:17:08 von
Beiträge: 3.632
ID: 1.041.671
ID: 1.041.671
Aufrufe heute: 9
Gesamt: 481.750
Gesamt: 481.750
Aktive User: 0
ISIN: US3755581036 · WKN: 885823 · Symbol: GILD
60,91
EUR
-0,28 %
-0,17 EUR
Letzter Kurs 19:32:32 Tradegate
Neuigkeiten
| Gilead Sciences Aktien jetzt im kostenlosen Demokonto handeln!Anzeige |
18:43 Uhr · Shareribs Anzeige |
30.04.24 · Business Wire (engl.)  |
30.04.24 · Shareribs Anzeige |
26.04.24 · Shareribs Anzeige |
Werte aus der Branche Pharmaindustrie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,2000 | +471,16 | |
| 0,5699 | +54,03 | |
| 13,110 | +38,44 | |
| 1,8250 | +35,19 | |
| 1,1514 | +30,84 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 4,5001 | -13,46 | |
| 1,5300 | -13,56 | |
| 46,00 | -19,44 | |
| 36,70 | -22,87 | |
| 2,7280 | -29,14 |
Beitrag zu dieser Diskussion schreiben
Feedback
Why Is the Stock Market Hanging Its Hopes on Gilead's Remdesivir?
Investors are waiting on pins and needles to see how the big biotech's experimental COVID-19 drug pans out.
Keith Speights
(TMFFishBiz)
Apr 26, 2020 at 9:01AM
Author Bio
Probably never before in history has the stock market's fortunes hinged in large part on the fate of one drug. But here we are. All eyes are on Gilead Sciences' (NASDAQ:GILD) antiviral drug remdesivir.
The Dow Jones Industrial Average rallied more than 700 points on April 17 after healthcare industry news website STAT reported encouraging results from a late-stage study of remdesivir in treating COVID-19. Those results weren't officially released, though. STAT's report relied on videoconference footage of a meeting with University of Chicago faculty involved in the study. But that didn't matter much to investors, who immediately celebrated the positive news.
When another report inadvertently posted on the World Health Organization (WHO) website on April 23 indicated that remdesivir didn't provide a clinical benefit to COVID-19 patients in a Chinese study, another stock market rally largely fizzled out.
Why is the stock market hanging its hopes on Gilead's remdesivir?
A magnifying glass over cubes spelling out Remdesivir
IMAGE SOURCE: GETTY IMAGES.
First-mover advantage
There are quite a few candidates for treating COVID-19. More than 20 publicly traded companies are working on evaluating drugs that could potentially treat the novel coronavirus disease. Several of these are large drugmakers that are household names in the U.S., including Bayer and Eli Lilly.
President Trump has spoken several times in press conferences about the potential for anti-malaria drugs chloroquine and hydroxychloroquine. Two reports, one in China for chloroquine and another in France for hydroxychloroquine, indicated that the drugs could be effective in treating COVID-19. In an international survey of doctors, hydroxychloroquine was voted as the most effective therapy for COVID-19 by 37% of respondents, making it the most highly rated treatment in the survey.
So why isn't the stock market rising and falling on news about these anti-malaria drugs or other potential COVID-19 candidates? It's simple: None of these other drugs is as far along as Gilead's remdesivir is in clinical studies that count. The previous studies of chloroquine and hydroxychloroquine didn't follow the protocols scientists use to make sure results are statistically significant. The FDA also recently warned about potential heart rhythm problems associated with the drugs.
Remdesivir, on the other hand, is already being evaluated in multiple late-stage clinical studies that were designed to achieve statistically significant results. Investors are also no doubt more interested in the drug because of its previously demonstrated potential in preclinical testing in treating other types of coronaviruses.
Results from one of Gilead's late-stage studies will be reported this month. The biotech will announce results from another late-stage study in May, around the same time that the U.S National Institute of Allergy and Infectious Disease (NIAID) will also report results from its own late-stage study of remdesivir. Because results from reputable clinical trials will be known so quickly, remdesivir enjoys a first-mover advantage in the eyes of investors.
Scientist looking through microscope
IMAGE SOURCE: GETTY IMAGES.
Gilead's Street cred
It also helps that Gilead Sciences boasts an impressive track record in treating viruses, giving the biotech a lot of credibility on Wall Street. The company's first drug, Vistide, was approved by the FDA in 1996 for treating retina inflammation caused by the human cytomegalovirus in patients with AIDS.
Gilead soon thereafter became a leader in treating the human immunodeficiency virus (HIV) that caused AIDS. The company's HIV drugs have dominated the market for two decades.
In late 2013, Gilead won FDA approval for Sovaldi. It was the first drug to effectively cure hepatitis C. Over the next few years, Gilead launched even more powerful multi-drug hepatitis C virus (HCV) therapies. The company's drugs were so effective that Gilead became a victim of its own success. So many patients with HCV were cured that the numbers of new patients to receive Gilead's therapies began to rapidly decline.
While Gilead is best known for its achievements in HIV and HCV, the biotech also was instrumental in the treatment of influenza. Gilead originally developed Tamiflu, a drug that is routinely given to prevent and treat flu. However, the company licensed the drug to Roche in 1996.
Left hanging?
In some ways, it makes sense that the stock market is hanging its hopes on remdesivir. A safe and effective treatment for COVID-19 would go a long way toward restoring confidence that life will return to normal. Gilead has earned respect from investors, and its experimental COVID-19 drug could meet the lofty expectations.
However, there's also a strong argument to be made that investors' hopes are misplaced. Remdesivir won't prevent people from getting COVID-19. Only a vaccine will achieve that goal. And the first vaccine is at least a year away and probably more. There's also a real chance that remdesivir won't be successful in treating COVID-19.
We'll soon know the results from Gilead's first late-stage study of remdesivir. It's likely that positive results will spark a stock market rally while disappointing results could cause another downswing. Wise investors will realize that the market tends to overreact. Any good news probably won't be as good as the hype. But bad news won't be as bad as it first appears, either.
Investors are waiting on pins and needles to see how the big biotech's experimental COVID-19 drug pans out.
Keith Speights
(TMFFishBiz)
Apr 26, 2020 at 9:01AM
Author Bio
Probably never before in history has the stock market's fortunes hinged in large part on the fate of one drug. But here we are. All eyes are on Gilead Sciences' (NASDAQ:GILD) antiviral drug remdesivir.
The Dow Jones Industrial Average rallied more than 700 points on April 17 after healthcare industry news website STAT reported encouraging results from a late-stage study of remdesivir in treating COVID-19. Those results weren't officially released, though. STAT's report relied on videoconference footage of a meeting with University of Chicago faculty involved in the study. But that didn't matter much to investors, who immediately celebrated the positive news.
When another report inadvertently posted on the World Health Organization (WHO) website on April 23 indicated that remdesivir didn't provide a clinical benefit to COVID-19 patients in a Chinese study, another stock market rally largely fizzled out.
Why is the stock market hanging its hopes on Gilead's remdesivir?
A magnifying glass over cubes spelling out Remdesivir
IMAGE SOURCE: GETTY IMAGES.
First-mover advantage
There are quite a few candidates for treating COVID-19. More than 20 publicly traded companies are working on evaluating drugs that could potentially treat the novel coronavirus disease. Several of these are large drugmakers that are household names in the U.S., including Bayer and Eli Lilly.
President Trump has spoken several times in press conferences about the potential for anti-malaria drugs chloroquine and hydroxychloroquine. Two reports, one in China for chloroquine and another in France for hydroxychloroquine, indicated that the drugs could be effective in treating COVID-19. In an international survey of doctors, hydroxychloroquine was voted as the most effective therapy for COVID-19 by 37% of respondents, making it the most highly rated treatment in the survey.
So why isn't the stock market rising and falling on news about these anti-malaria drugs or other potential COVID-19 candidates? It's simple: None of these other drugs is as far along as Gilead's remdesivir is in clinical studies that count. The previous studies of chloroquine and hydroxychloroquine didn't follow the protocols scientists use to make sure results are statistically significant. The FDA also recently warned about potential heart rhythm problems associated with the drugs.
Remdesivir, on the other hand, is already being evaluated in multiple late-stage clinical studies that were designed to achieve statistically significant results. Investors are also no doubt more interested in the drug because of its previously demonstrated potential in preclinical testing in treating other types of coronaviruses.
Results from one of Gilead's late-stage studies will be reported this month. The biotech will announce results from another late-stage study in May, around the same time that the U.S National Institute of Allergy and Infectious Disease (NIAID) will also report results from its own late-stage study of remdesivir. Because results from reputable clinical trials will be known so quickly, remdesivir enjoys a first-mover advantage in the eyes of investors.
Scientist looking through microscope
IMAGE SOURCE: GETTY IMAGES.
Gilead's Street cred
It also helps that Gilead Sciences boasts an impressive track record in treating viruses, giving the biotech a lot of credibility on Wall Street. The company's first drug, Vistide, was approved by the FDA in 1996 for treating retina inflammation caused by the human cytomegalovirus in patients with AIDS.
Gilead soon thereafter became a leader in treating the human immunodeficiency virus (HIV) that caused AIDS. The company's HIV drugs have dominated the market for two decades.
In late 2013, Gilead won FDA approval for Sovaldi. It was the first drug to effectively cure hepatitis C. Over the next few years, Gilead launched even more powerful multi-drug hepatitis C virus (HCV) therapies. The company's drugs were so effective that Gilead became a victim of its own success. So many patients with HCV were cured that the numbers of new patients to receive Gilead's therapies began to rapidly decline.
While Gilead is best known for its achievements in HIV and HCV, the biotech also was instrumental in the treatment of influenza. Gilead originally developed Tamiflu, a drug that is routinely given to prevent and treat flu. However, the company licensed the drug to Roche in 1996.
Left hanging?
In some ways, it makes sense that the stock market is hanging its hopes on remdesivir. A safe and effective treatment for COVID-19 would go a long way toward restoring confidence that life will return to normal. Gilead has earned respect from investors, and its experimental COVID-19 drug could meet the lofty expectations.
However, there's also a strong argument to be made that investors' hopes are misplaced. Remdesivir won't prevent people from getting COVID-19. Only a vaccine will achieve that goal. And the first vaccine is at least a year away and probably more. There's also a real chance that remdesivir won't be successful in treating COVID-19.
We'll soon know the results from Gilead's first late-stage study of remdesivir. It's likely that positive results will spark a stock market rally while disappointing results could cause another downswing. Wise investors will realize that the market tends to overreact. Any good news probably won't be as good as the hype. But bad news won't be as bad as it first appears, either.
Antwort auf Beitrag Nr.: 63.455.012 von mr11x am 26.04.20 09:29:56Das wirklich Wichtige ist doch folgendes:
Der Laden ist nicht hoch bewertet, er zahlt zuverlässig Dividende und er ist profitabel, unabhängig davon, ob das jetzt klappt oder nicht.
Viele Biotechfirmen zahlen nichts, sind nicht profitabel oder sehr hoch bewertet.
Also ist das schon von daher ein Kauf...
...klappt es dann auch noch mit dem Remdesivir, dann ist es noch besser.
Der Laden ist nicht hoch bewertet, er zahlt zuverlässig Dividende und er ist profitabel, unabhängig davon, ob das jetzt klappt oder nicht.
Viele Biotechfirmen zahlen nichts, sind nicht profitabel oder sehr hoch bewertet.
Also ist das schon von daher ein Kauf...
...klappt es dann auch noch mit dem Remdesivir, dann ist es noch besser.
Antwort auf Beitrag Nr.: 63.437.795 von abgemeldet-577022 am 24.04.20 08:38:08Ich sehe in diesem Fall das Gild Glas eher halbvoll: . Wenn es mit dem Corona Medikament klappen sollte, dann kann man als Aktionär vielleicht so einen raren sogenannten "dausender" Aktienanstiegsmoment mitmachen. Wird bei meiner kleinen Position kein gamechanger für mich sein, würde aber zB meiner besseren Hälfte und mir ;-) danach mit einem Teil des Gewinns irgendeinen harmlosen kleinen Konsum gönnen um die post Corona Wirtschaft wieder anzukurbeln
Wenns mit dem Medikament nicht klappen sollte, immerhin gibt es rund 150 offizielle Konkurrenten auf der globalen shortliste , dann werde ich Gild behalten und bei Absturz nachkaufen, da Gild kein Corona one trick pony ist wie aus einem anderen Forum rauskopiert bzw wie man auch an deren product pipeline für kommende potentielle Medikamente sehen kann , veröffentlicht auf der Gild Seite https://www.gilead.com/science-and-medicine/pipeline
If you really believe GILD is undervalued now, you will not blame leaked report, blame WHO and China. If remdmesivir works, all other on-going trials will prove it. If not, to be it. You bought GILD just on remdmesivir, sorry for you.
Five bGreat Reasons to Buy Gilead Sciences Stock
1. A big sale increase in the near future.
Gilead will likely receive approval from U.S. FDA, Japan and European regulators for filgotinib in treating rheumatoid arthritis. Multibillion sale a year. With acquiring Forty Seven recently, a potential increase sale in Oncology field.
2. Low PE ratio, far less violate stock. Current PE ratio: GILD 12.66 ($84/6.63 for 2020), S&P 500 PE ratio: 20.41
3. High dividend. GILD pays current dividend 3.2%, few Biotech can match that rate.
4. Strong pipeline new drug candidates in late stage clinical trials.
Inflammatory diseases: Filgotinib, Ulcerative colitis Phase III; Crohn's disease, Phase III; Psoriatic arthritis, phase III; Ankylosing spondylitis, phase III; Uveitis, phase III.
TPL2 inhibitor, phase II; GLPG-1972, phaseII.
Fibrotic Diseases, Cilofexor (GS-9674, FXR agonist), PSC, Phase III; GLPG-1690, idiopathic Pulmonary Fibrosis, phase III; Cilofexor (FXR agonist), NASH, phase II; Firsocostat (ACC inhibitor), NASH, phase II; Selonsertib (ASK1 inhibitor) combinations, DKD, phase II; GLPG-16901) Systemic sclerosis, phase II; GLPG-12052, Idiopathic pulmonary fibrosis, phase II;
Oncology
KTE-X19, MCL, phase III; Axi-cel,2L DLBCL, phase III; Axi-cel, 1L DLBCL, DLBCL (+rituximab or lenalidomide), Adult ALL, Pediatric ALL, Indolent NHL, phase II.
5. Remdmeivir, Potential drug for Covid-19, may bring billion revenue for the company.
Wenns mit dem Medikament nicht klappen sollte, immerhin gibt es rund 150 offizielle Konkurrenten auf der globalen shortliste , dann werde ich Gild behalten und bei Absturz nachkaufen, da Gild kein Corona one trick pony ist wie aus einem anderen Forum rauskopiert bzw wie man auch an deren product pipeline für kommende potentielle Medikamente sehen kann , veröffentlicht auf der Gild Seite https://www.gilead.com/science-and-medicine/pipeline
If you really believe GILD is undervalued now, you will not blame leaked report, blame WHO and China. If remdmesivir works, all other on-going trials will prove it. If not, to be it. You bought GILD just on remdmesivir, sorry for you.
Five bGreat Reasons to Buy Gilead Sciences Stock
1. A big sale increase in the near future.
Gilead will likely receive approval from U.S. FDA, Japan and European regulators for filgotinib in treating rheumatoid arthritis. Multibillion sale a year. With acquiring Forty Seven recently, a potential increase sale in Oncology field.
2. Low PE ratio, far less violate stock. Current PE ratio: GILD 12.66 ($84/6.63 for 2020), S&P 500 PE ratio: 20.41
3. High dividend. GILD pays current dividend 3.2%, few Biotech can match that rate.
4. Strong pipeline new drug candidates in late stage clinical trials.
Inflammatory diseases: Filgotinib, Ulcerative colitis Phase III; Crohn's disease, Phase III; Psoriatic arthritis, phase III; Ankylosing spondylitis, phase III; Uveitis, phase III.
TPL2 inhibitor, phase II; GLPG-1972, phaseII.
Fibrotic Diseases, Cilofexor (GS-9674, FXR agonist), PSC, Phase III; GLPG-1690, idiopathic Pulmonary Fibrosis, phase III; Cilofexor (FXR agonist), NASH, phase II; Firsocostat (ACC inhibitor), NASH, phase II; Selonsertib (ASK1 inhibitor) combinations, DKD, phase II; GLPG-16901) Systemic sclerosis, phase II; GLPG-12052, Idiopathic pulmonary fibrosis, phase II;
Oncology
KTE-X19, MCL, phase III; Axi-cel,2L DLBCL, phase III; Axi-cel, 1L DLBCL, DLBCL (+rituximab or lenalidomide), Adult ALL, Pediatric ALL, Indolent NHL, phase II.
5. Remdmeivir, Potential drug for Covid-19, may bring billion revenue for the company.
Meldung von heute, und die Betonung liegt auf "zurückhaltenden Schätzungen". Es sieht also alles sehr gut aus.
"Gibt es einen Medikamenten-Durchbruch? Frühe Studiendaten zur Therapie der Lungenkrankheit Covid-19 mit dem Medikament Remdesivir haben für Wirbel gesorgt. Die Wirkung des ursprünglich gegen Ebola entwickelten US-Präparats wird derzeit weltweit untersucht. Kurzzeitig führten Medienberichte zu Aufruhr, nach denen das Mittel keinen Erfolg brachte. Hersteller wie Mediziner warnen nun vor voreiligen Schlüssen. Das Medikament habe bei Patienten in der München Klinik Schwabing erste Erfolge gebracht, sagte Clemens Wendtner, Chefarzt der dortigen Klinik für Infektiologie.
Nach zurückhaltenden Schätzungen habe die Hälfte seiner Patienten profitiert, sagte Wendtner. Es sehe danach aus, dass schwer Erkrankte früher von den Beatmungsmaschinen genommen werden könnten."
https://www.tz.de/muenchen/stadt/coronavirus-muenchen-masken…
"Gibt es einen Medikamenten-Durchbruch? Frühe Studiendaten zur Therapie der Lungenkrankheit Covid-19 mit dem Medikament Remdesivir haben für Wirbel gesorgt. Die Wirkung des ursprünglich gegen Ebola entwickelten US-Präparats wird derzeit weltweit untersucht. Kurzzeitig führten Medienberichte zu Aufruhr, nach denen das Mittel keinen Erfolg brachte. Hersteller wie Mediziner warnen nun vor voreiligen Schlüssen. Das Medikament habe bei Patienten in der München Klinik Schwabing erste Erfolge gebracht, sagte Clemens Wendtner, Chefarzt der dortigen Klinik für Infektiologie.
Nach zurückhaltenden Schätzungen habe die Hälfte seiner Patienten profitiert, sagte Wendtner. Es sehe danach aus, dass schwer Erkrankte früher von den Beatmungsmaschinen genommen werden könnten."
https://www.tz.de/muenchen/stadt/coronavirus-muenchen-masken…
Nach Informationen handelt es sich um eine gezielte Desinformation von chinesischer Seite. Mutmaßlich als Vergeltung für die Kritik, die US-Präsident Donald Trump (73) zuletzt am Regime und auch an der WHO äußerte.
Im Hintergrund tobt zudem ein Patent-Streit zwischen Gilead und den chinesischen Machthabern. Die WHO hat die umstrittene Studie inzwischen von ihrer Internetseite gelöscht.
Im Hintergrund tobt zudem ein Patent-Streit zwischen Gilead und den chinesischen Machthabern. Die WHO hat die umstrittene Studie inzwischen von ihrer Internetseite gelöscht.
Trading Spotlight
Nach enttäuschender China-Studie
Münchener Klinik hat Erfolge mit Remdesivit
https://www.n-tv.de/panorama/Muenchener-Klinik-hat-Erfolge-m…
Münchener Klinik hat Erfolge mit Remdesivit
https://www.n-tv.de/panorama/Muenchener-Klinik-hat-Erfolge-m…
Leute sowohl Trendanalyse/Charttechnik (Vgl. Trend-Chart) als auch Analytik versprechen mir, daß der Gilead-Kurs bald die 100$ knacken wird. Niemand ist mit einem Medikament besser positioniert als Gilead.
Antwort auf Beitrag Nr.: 63.447.749 von Hartgeldinvestor am 24.04.20 21:27:49Der WHO gehört der Geldhahn abgedreht - und das nicht nur von den USA, sondern weltweit.
Diesen Laden braucht kein Mensch und schon gar nicht die Witzfigur, die da den Chef gibt.
Diesen Laden braucht kein Mensch und schon gar nicht die Witzfigur, die da den Chef gibt.
Antwort auf Beitrag Nr.: 63.447.737 von Hartgeldinvestor am 24.04.20 21:26:40
Und das Zitat natürlich noch:
"Nach BILD-Informationen handelt es sich um eine gezielte Desinformation von chinesischer Seite. Mutmaßlich als Vergeltung für die Kritik, die US-Präsident Donald Trump (73) am Regime äußerte."
Zitat von Hartgeldinvestor: Ich halte nichts von der Bild, aber hier die Schlagzeile von heut Abend. Bin mal gespannt was da dran ist.
https://www.bild.de/politik/inland/politik-inland/coronakris…
Und das Zitat natürlich noch:
"Nach BILD-Informationen handelt es sich um eine gezielte Desinformation von chinesischer Seite. Mutmaßlich als Vergeltung für die Kritik, die US-Präsident Donald Trump (73) am Regime äußerte."
Ich halte nichts von der Bild, aber hier die Schlagzeile von heut Abend. Bin mal gespannt was da dran ist.
https://www.bild.de/politik/inland/politik-inland/coronakris…
https://www.bild.de/politik/inland/politik-inland/coronakris…
Durchsuchen
GILEAD SCIENCES 885823
